Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts
ConclusionThe safety profile of glecaprevir/pibrentasvir enhances the confidence of non-liver specialists to treat the majority of HCV-infected patients, and provides an opportunity to expand the treater pool, potentially increasing diagnosis and treatment rates for HCV, contributing to elimination of HCV.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Carcinoma | Cirrhosis | Clinical Trials | Drugs & Pharmacology | Hepatitis | Hepatitis A | Hepatocellular Carcinoma | Laboratory Medicine | Liver | Liver Cancer | Liver Disease | Oral Cancer | Study | Urology & Nephrology